[go: up one dir, main page]

JO3705B1 - إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية - Google Patents

إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية

Info

Publication number
JO3705B1
JO3705B1 JOP/2015/0287A JOP20150287A JO3705B1 JO 3705 B1 JO3705 B1 JO 3705B1 JO P20150287 A JOP20150287 A JO P20150287A JO 3705 B1 JO3705 B1 JO 3705B1
Authority
JO
Jordan
Prior art keywords
medicaments
processes
preparation
production
endometriosis
Prior art date
Application number
JOP/2015/0287A
Other languages
English (en)
Inventor
Reinhard Nubbemeyer Dr
Martin Lange Dr
Alexandra Rausch Dr
Holger Steuber Dr
Friedrich Christian
Ulf B?Mer Dr
Andreas Sutter Dr
Hauff Peter
Nicole Schmidt Dr
Holger Siebeneicher Dr
Judith Gunther Dr
Christian Stegmann Dr
Ulrich Bothe Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3705B1 publication Critical patent/JO3705B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الطلب الحالي بمركبات indazoles مستبدلة جديدة، بعمليات لتحضيرها، باستخدامها بمفردها أو في اتحاد لمعالجة /أو الوقاية من أمراض، وباستخدامها في إنتاج أدوية لمعالجة و/أو الوقاية من أمراض، خصوصا معالجة و/أو الوقاية من الانتباذ البطاني الرحمي والألم المصاحب للانتباذ البطاني الرحمي والأعراض المصاحبة للانتباذ البطاني الرحمي الأخرى مثل عسر الطمث، عسر الجماع، عسر التبول وعسر التغوط، الليمفوما، التهاب المفاصل الروماتويدي، التهاب المفاصل الفقارية (خصوصا التهاب المفاصل الفقارية الصدفي ومرض Bekhterev)، الذئبة الحمامية النظامية، التصلب المتعدد، التحلل البقعي، COPD (مرض الإعاقة الرئوية المزمنة (chronic obstructive pulmonary disease))، النقرس، اضطرابات الكبد الدهني، مقاومة الإنسولين، الاضطرابات الورمية والصدفية.
JOP/2015/0287A 2014-11-26 2015-11-23 إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية JO3705B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26

Publications (1)

Publication Number Publication Date
JO3705B1 true JO3705B1 (ar) 2021-01-31

Family

ID=51982455

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0287A JO3705B1 (ar) 2014-11-26 2015-11-23 إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية

Country Status (42)

Country Link
US (6) US10308634B2 (ar)
EP (3) EP3674298B9 (ar)
JP (1) JP6496823B2 (ar)
KR (1) KR102083857B1 (ar)
CN (2) CN110305109B (ar)
AR (1) AR102827A1 (ar)
AU (2) AU2015352603B2 (ar)
BR (2) BR112017011005B1 (ar)
CA (1) CA2968614C (ar)
CL (1) CL2017001364A1 (ar)
CO (1) CO2017005374A2 (ar)
CR (1) CR20170220A (ar)
CU (1) CU24448B1 (ar)
CY (1) CY1123815T1 (ar)
DK (2) DK3224254T3 (ar)
DO (1) DOP2017000127A (ar)
EA (1) EA032509B1 (ar)
EC (1) ECSP17032530A (ar)
ES (2) ES2976932T3 (ar)
FI (1) FI3674298T3 (ar)
HR (2) HRP20200974T1 (ar)
HU (2) HUE065938T2 (ar)
IL (3) IL252185B (ar)
JO (1) JO3705B1 (ar)
LT (2) LT3674298T (ar)
MA (1) MA41011B1 (ar)
ME (1) ME03745B (ar)
MX (2) MX380150B (ar)
NI (1) NI201700063A (ar)
NZ (1) NZ732126A (ar)
PE (1) PE20171376A1 (ar)
PH (1) PH12017500972A1 (ar)
PL (2) PL3674298T3 (ar)
PT (2) PT3674298T (ar)
RS (2) RS65327B1 (ar)
SG (3) SG10201903474PA (ar)
SI (2) SI3674298T1 (ar)
TN (1) TN2017000226A1 (ar)
TW (2) TWI717061B (ar)
UA (2) UA120948C2 (ar)
UY (1) UY36411A (ar)
WO (1) WO2016083433A1 (ar)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505337A (ja) 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
AU2015205374B2 (en) 2014-01-13 2018-08-23 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) * 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
EP3195865A1 (de) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
EP3448848B1 (en) * 2016-04-29 2023-09-27 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
PT3448849T (pt) * 2016-04-29 2020-06-30 Bayer Pharma AG Síntese de indazóis
TN2018000409A1 (en) * 2016-06-01 2020-06-15 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
ES2898771T3 (es) * 2016-06-01 2022-03-08 Bayer Animal Health Gmbh Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
RS64411B1 (sr) 2017-03-31 2023-09-29 Aurigene Oncology Ltd Jedinjenja i kompozicije za lečenje hematoloških poremećaja
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
PE20200756A1 (es) 2017-08-16 2020-07-27 Univ Vanderbilt Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN112262132A (zh) 2018-06-27 2021-01-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020035019A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 吲唑胺类衍生物及其制备方法和其在医药上的用途
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
WO2020135513A1 (zh) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113825755B (zh) * 2019-06-26 2023-04-25 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
AR119244A1 (es) * 2019-06-27 2021-12-01 Biogen Ma Inc Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
TW202116754A (zh) 2019-07-11 2021-05-01 美商Ｅ 斯蓋普生物股份有限公司 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
WO2021057785A1 (zh) * 2019-09-24 2021-04-01 上海美悦生物科技发展有限公司 一种irak抑制剂及其制备方法和用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
EP4366834A1 (en) * 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
CN118302425A (zh) * 2021-12-03 2024-07-05 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
CN119894895A (zh) 2022-11-04 2025-04-25 领泰生物医药(绍兴)有限公司 Irak4降解剂及其用途
AU2023379702A1 (en) * 2022-11-17 2025-06-05 Elanco Animal Health Gmbh Methods and compositions for control of pain and inflammation
CN116120283B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途
KR20250004525A (ko) * 2023-06-29 2025-01-08 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
RU2005105683A (ru) * 2002-07-31 2006-01-20 Шеринг Акциенгезельшафт (De) Обладающие ингибирующим действием на vegfr-2 и vegfr-3 антраниламидопиридины
US20070179143A1 (en) 2003-06-25 2007-08-02 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2591332A1 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
WO2007091107A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
WO2008001883A1 (en) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
CA2663100A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
EP2507226A1 (en) * 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
CA2822166C (en) 2010-12-20 2019-10-29 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP2017505337A (ja) 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
MX2016017147A (es) 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
KR20180025896A (ko) 2015-07-15 2018-03-09 오리진 디스커버리 테크놀로지스 리미티드 Irak-4 저해제로서 인다졸 및 아자인다졸 화합물
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
PT3448849T (pt) 2016-04-29 2020-06-30 Bayer Pharma AG Síntese de indazóis
EP3448848B1 (en) 2016-04-29 2023-09-27 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
TN2018000409A1 (en) 2016-06-01 2020-06-15 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
ES2898771T3 (es) 2016-06-01 2022-03-08 Bayer Animal Health Gmbh Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales

Also Published As

Publication number Publication date
NZ732126A (en) 2018-09-28
PL3674298T3 (pl) 2024-06-24
JP2017535585A (ja) 2017-11-30
IL267537A (en) 2019-08-29
HRP20200974T1 (hr) 2020-10-02
ECSP17032530A (es) 2017-06-30
EA201791137A1 (ru) 2017-11-30
UA120948C2 (uk) 2020-03-10
HUE065938T2 (hu) 2024-06-28
KR102083857B1 (ko) 2020-03-03
UY36411A (es) 2016-06-30
CL2017001364A1 (es) 2017-12-15
EP3224254A1 (de) 2017-10-04
EA032509B1 (ru) 2019-06-28
CU20170073A7 (es) 2017-10-05
LT3674298T (lt) 2024-04-10
CN107406416B (zh) 2020-04-21
ES2976932T3 (es) 2024-08-13
ME03745B (me) 2021-04-20
SG11201704092YA (en) 2017-06-29
HRP20240414T1 (hr) 2024-06-21
MX2020010623A (es) 2022-02-16
US20170349570A1 (en) 2017-12-07
DK3224254T3 (da) 2020-07-13
WO2016083433A1 (de) 2016-06-02
AU2020200979B2 (en) 2021-01-07
CN110305109A (zh) 2019-10-08
US20250034111A1 (en) 2025-01-30
RS60284B1 (sr) 2020-06-30
TW201629037A (zh) 2016-08-16
US20220388982A1 (en) 2022-12-08
CA2968614C (en) 2019-10-29
AR102827A1 (es) 2017-03-29
BR122021002613B1 (pt) 2023-04-11
TWI689502B (zh) 2020-04-01
TN2017000226A1 (en) 2018-10-19
US20190233395A1 (en) 2019-08-01
ES2796285T3 (es) 2020-11-26
BR112017011005B1 (pt) 2023-03-14
TW202002973A (zh) 2020-01-16
CO2017005374A2 (es) 2017-08-31
DOP2017000127A (es) 2017-07-31
EP4260909A3 (de) 2024-03-20
US10793545B2 (en) 2020-10-06
CY1123815T1 (el) 2022-03-24
EP3224254B1 (de) 2020-04-15
HUE049341T2 (hu) 2020-09-28
US12006303B2 (en) 2024-06-11
EP3674298B9 (de) 2024-06-19
ES2976932T9 (es) 2024-09-05
CU24448B1 (es) 2019-10-04
IL267537B (en) 2020-07-30
PT3674298T (pt) 2024-04-01
EP3674298B1 (de) 2024-01-10
LT3224254T (lt) 2020-06-10
IL252185A0 (en) 2017-07-31
IL252185B (en) 2019-10-31
TWI717061B (zh) 2021-01-21
AU2015352603B2 (en) 2020-04-02
RS65327B1 (sr) 2024-04-30
SG10201903475TA (en) 2019-05-30
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
DK3674298T3 (da) 2024-04-08
AU2020200979A1 (en) 2020-02-27
US12006304B2 (en) 2024-06-11
SI3674298T1 (sl) 2024-05-31
MX2017006910A (es) 2017-08-15
US10308634B2 (en) 2019-06-04
MA41011B1 (fr) 2020-08-31
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
FI3674298T3 (fi) 2024-04-17
BR112017011005A2 (pt) 2019-05-14
CR20170220A (es) 2017-10-31
IL269444B (en) 2020-07-30
EP4260909A2 (de) 2023-10-18
US20230174508A1 (en) 2023-06-08
CN107406416A (zh) 2017-11-28
PT3224254T (pt) 2020-06-17
SG10201903474PA (en) 2019-05-30
UA123813C2 (uk) 2021-06-02
AU2015352603A1 (en) 2017-06-01
SI3224254T1 (sl) 2020-07-31
MX390119B (es) 2025-03-20
EP3674298A1 (de) 2020-07-01
MX380150B (es) 2025-03-12
PL3224254T3 (pl) 2020-09-21
CN110305109B (zh) 2022-04-08
JP6496823B2 (ja) 2019-04-10
IL269444A (en) 2019-11-28
CA2968614A1 (en) 2016-06-02
US20210053941A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JO3705B1 (ar) إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
UY37048A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
NZ753881A (en) Treatment of neurological diseases
MX2019006429A (es) Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2023008075A (es) Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.
HK1257935A1 (zh) 氨基糖苷衍生物及其在治疗遗传性病症中的应用
EP4406969A3 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
CY1122061T1 (el) Χιμαιρικος διαλυτος υποδοχεας ιντερλευκινης-10 και θεραπευτικη χρηση αυτου
WO2016199170A3 (en) Paliperidone palmitate particles and compositions thereof
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
UA115887U (xx) Спосіб терапії порушень фолікулогенезу у хворих на синдром полікістозних яєчників
HK1240487A1 (en) Methods for formulating antibody drug conjugate compositions
PL409386A1 (pl) Preparaty peptydowe do zastosowania jako środek farmaceutyczny lub dodatek do żywności w zapobieganiu i leczeniu chorób neurodegeneracyjnych